SCHEMBL22441633

SCHEMBL22441633

Cc1ccc(NC(=O)C=Cc2cccc(C(=O)Nc3cccc(C(F)(F)F)c3)c2)nc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.62
▸ KMT2A Q03164 5/20 0.62
▸ MAPT P10636 2/20 0.59
▸ LMNA P02545 2/20 0.59
▸ HSP90AA1 P07900 1/20 0.59
▸ PKM P14618 1/20 0.59
▸ NPSR1 Q6W5P4 1/20 0.59
▸ HTT P42858 2/20 0.58
▸ KIT P10721 3/20 0.54
▸ KDR P35968 3/20 0.54
▸ MAPK14 Q16539 3/20 0.54
▸ RAB9A P51151 2/20 0.53
▸ KCNK3 O14649 1/20 0.53
▸ KCNK9 Q9NPC2 1/20 0.53
▸ MAOB P27338 1/20 0.53
▸ LCK P06239 3/20 0.50
▸ BTK Q06187 2/20 0.50
▸ PTGS1 P23219 1/20 0.50
▸ THRB P10828 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22441632 1.00 MEN1 (0.62) MEN1KMT2AMAPTLMNAHSP90AA1
SCHEMBL22441690 0.89 MEN1 (0.59) MEN1KMT2AMAPTLMNAHSP90AA1
SCHEMBL22441674 0.89 MEN1 (0.59) MEN1KMT2AMAPTLMNAHSP90AA1
SCHEMBL22441675 0.89 MEN1 (0.59) MEN1KMT2AMAPTLMNAHSP90AA1
SCHEMBL22441687 0.89 MEN1 (0.59) MEN1KMT2AMAPTLMNAHSP90AA1
SCHEMBL22455486 0.88 MAPT (0.53) MEN1KMT2AMAPTLMNAHSP90AA1
SCHEMBL22441822 0.87 MEN1 (0.54) MEN1KMT2AMAPTLMNAHSP90AA1
SCHEMBL22441820 0.87 MEN1 (0.54) MEN1KMT2AMAPTLMNAHSP90AA1
SCHEMBL22441752 0.86 MEN1 (0.56) MEN1KMT2AMAPTLMNAHSP90AA1
SCHEMBL22441751 0.86 MEN1 (0.56) MEN1KMT2AMAPTLMNAHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200299282-A1 COMPOUNDS AND METHODS FOR TREATING CANCER ANTIDOTE IP HOLDINGS LLC (US) 2020-09-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200299282-A1 COMPOUNDS AND METHODS FOR TREATING CANCER VHL, TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MEN1 364/4885KMT2A 702/4885MAPT 3913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback